Skip to main content

Remote Job Finders (RJF)

How Abogen went from COVID hype to a $7.8B Novartis deal

After Abogen Biosciences’ COVID shot missed the commercial window, the big question was whether its mRNA technology could create value beyond vaccines. Novartis’ $575 million upfront commitment is the clearest external validation yet of that broader therapeutic potential.
Scroll to top